Inactive Instrument

Other languages Xenetic Biosciences Inc Nasdaq

Equities

US9840152063

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Xenetic Biosciences, Inc. Announces Management Resignations	23/05
Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	23/05
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
CLS Therapeutics Discloses its Views on Xenetic Biosciences	18/03
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	17/01
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Xenetic Biosciences to Implement 1-for-10 Reverse Split	13/23/13
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	11/23/11
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	16/22/16
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	04/22/04
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	02/22/02
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	07/22/07
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13
Xenetic Biosciences, Inc. Enters into Sublicense Agreement with CLS Therapeutics Ltd	27/22/27
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	23/22/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xenetic Biosciences Inc Nasdaq

Equities

US9840152063

Other languages

Filters